Gynesonics aims for $35M for minimally invasive uterine fibroid device

A model of a procedure that treats uterine fibroids using the VizAblate--Courtesy of Gynesonics

Gynesonics has raised an additional $6 million in its march toward raising a total round of $35.5 million in equity and debt, according to an SEC filing. That brings this financing total to more than $28 million, from the roughly $22 million it had raised last February that included a Series D venture round.

The additional cash is timely, coming on the heels of its receipt of a European CE mark for and treatment of the first patient with its next-generation VizAblate System in June. If approved in the U.S., the system could provide a minimally invasive alternative to the controversial power morcellators, which are the subject of an FDA panel review this week after concerns were raised about a potential increased cancer risk associated with their use.

VizAblate is a transcervical treatment of symptomatic uterine fibroids guided by intrauterine ultrasound. It is a handheld device for radio-frequency ablation and works on larger and deeper fibroids than other transcervical methods, according to the company.

About 70% to 80% of U.S. women will develop uterine fibroids by age 50, with about 200,000 hysterectomies performed annually because of symptomatic fibroids.

Investors may be preparing down the road for an M&A exit. In April, Gynesonics appointed Christopher Owens as president and CEO; he previously held those titles with medical device company IDEV Technologies, which was acquired by Abbott Laboratories ($ABT) for $310 million in 2013.

Venture investors in Gynesonics include HBM Partners, which led the Series D round, as well as Abingworth, ATV Capital, Correlation Partners and InterWest Partners.

- here is the SEC filing

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.